2022 Annual Meeting | C120 - Multiple Sclerosis Disease-modifying Treatment

Date Wednesday 04/06/22

Time 07:00 AM - 09:00 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Jacqueline Bernard, MD, FAAN

Topic(s) Multiple Sclerosis

Learning Objectives Participants should be comfortable with selecting DMTs based on risk stratification, including pregnancy and family planning for RRMS, SPMS, and PPMS; understand complications associated with approved DMTs in RRMS, SPMS, and PPMS; creating an algorithm for patients who break through therapies and no longer meet "NEDA" criteria; and the impact of COVID-19 disease and vaccination on DMT doses.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Medical Student

Teaching Styles Didactic

Program Materials Program Evaluations

Event Timeline
07:00 AM - 09:00 AM PDT	Speaker	Multiple Sclerosis Disease-modifying Treatment Jacqueline Bernard, MD, FAAN, Michael A. Lane, MD
07:00 AM - 07:00 AM PDT	Speaker	Walk-in Slides Jacqueline Bernard, MD, FAAN

Faculty Disclosures
Jacqueline Bernard, MD, FAAN	Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bernard has received publishing royalties from a publication relating to health care.
Michael A. Lane, MD	Dr. Lane has nothing to disclose.